This is a "connection" page, showing publications co-authored by Terry Day and Elizabeth Garrett-Mayer.
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105.
Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer. Laryngoscope. 2010 Feb; 120(2):236-42.
Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. 2009 Apr; 31(4):493-502.
Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. 2008 Jul; 118(7):1180-5.